ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NNNN vs QDEL // EV/EBITDA & P/E VALUATION

Anbio Biotechnology (Class A) (NASDAQ) VS. QuidelOrtho Corporation (NASDAQ) • 15-METRIC TALLY: NNNN 6 — QDEL 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. QDEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NNNN QDEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 17.00% -35.00% +52.00 NNNN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 91.5x — — TIE /valuation <GO>
Free Cash Flow Yield -1.26% -8.80% +7.54 NNNN /fcf-yield <GO>
Operating Margin 66.70% -33.70% +100.40 NNNN /operating-margins <GO>
Net Profit Margin 68.00% -41.50% +109.50 NNNN /net-margins <GO>
Revenue Growth (YoY) 5.60% -1.90% +7.50 NNNN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 NNNN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.4 51.1 -21.64 QDEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 77.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $535.3M $943.6M -$408.3M QDEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NNNN REV QDEL REV NNNN GROSS % QDEL GROSS % NNNN FCF QDEL FCF
FY 2025 $8.6M $2.73B 87.2% — -$6.7M -$83.0M
FY 2024 $8.2M $2.78B 71.9% — $2.1M -$112.1M
FY 2023 $6.7M $3.00B — — $898.4K $280.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
QDEL // BETA —